An interventional study of ReNu Injection and Corticosteroid Injection in Fasciitis, Plantar, sponsored by NuTech Medical, Inc. Status unknown at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-21.
Sponsored by NuTech Medical, Inc · Not applicable, Interventional, and Treatment
The objective of this clinical trial is to evaluate both the safety and efficacy of the ReNu™ injection on pain and inflammation in subjects diagnosed with plantar fasciitis as compared to a Corticosteroid Injection which is considered standard of care.
This is a two (2) arm evaluation in 150 subjects with plantar fasciitis. Patients will be treated with ReNu™(study treatment) or Corticosteroids (control).
At each follow-up visit, concomitant medications and adverse events shall be collected from each subject, and each subject shall complete following questionnaires:
The subjects will be assessed at Baseline (pre-injection) using these scales and again at all subsequent study follow-up visits.
235 studies on the registry are indexed under Fasciitis; 37 are open to participants now.
This study's planned enrollment of 150 is above the median of 54 across 192 interventional studies indexed under Fasciitis.
Browse Fasciitis studies →NuTech Medical, Inc is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Presence of comorbidities that can be confused with or can exacerbate the condition including, but not limited to the following:
Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
Other: ReNu Injection
Plantar Fascia injection with Corticosteroids.
Other: Corticosteroid Injection
ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
Change in AOFAS score from baseline
Time frame: 6 months
Change in VAS pain score from baseline
Time frame: 6 months
Change in SANE function score from baseline
Time frame: 6 months
Return to Normal Function between treatment groups
Assessed using questionnaire by the Principal Investigator (PI)
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NuTech Medical, Inc